Resource Library
New to the Resource Library?
Learn how to navigate, search, and use our resources effectively.
Amicus Curiae Brief in Support of Respondent on Review by Amicus Drug Policy Alliance
This brief argues that using only drug weight and packaging to prove intent to deliver unfairly treats drug possession as attempted delivery. It states these factors are unreliable indicators of an intent to sell.
Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: A cohort study
People released from prison are at high risk for overdose. This study found that a history of stimulant use disorder reduced the likelihood of receiving critical opioid addiction treatment within two days of release in British Columbia.
Neural substrates of substance use disorders
Subcortical disease and lack of prefrontal control are common findings in neuroimaging studies of substance use. It is still unclear if these are pre-existing traits or consequences of substance use.
Structural and functional brain recovery in individuals with substance use disorders during abstinence: A review of longitudinal neuroimaging studies
This review focuses on longitudinal neuroimaging studies to understand how the brain changes during abstinence from substance use. It aims to identify mechanisms associated with sustained abstinence or relapse.
Impact of Substance Use Disorder on Between-Network Brain Connectivity in Early Psychosis
Psychotic disorders involve brain network dysconnectivity, with abnormalities in salience, default mode, and central executive networks. Substance use may worsen these connectivity issues and influence symptom severity.
Advances in neuroimaging studies of Alcohol Use Disorder (AUD)
Neuroimaging reveals alcohol use disorder (AUD) patients experience reduced gray matter volume, especially in frontal brain regions, and significant white matter changes. Abstinence can partially reverse these brain deficits.
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Psychedelic drugs show promise for treating mental disorders, including depression and addiction. Research is exploring how these substances affect the brain and mind at different levels to understand their therapeutic potential.
Psychedelics and health behaviour change
Psychedelic compounds are being explored as tools to promote healthier lifestyles and treat various conditions. Research from past decades and renewed 21st-century studies show promising results for treating mood disorders and addictions.
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Psychedelic medicines are gaining attention for medical use, leading to regulatory changes in the US and Canada. This review examines potential risks, aiming to distinguish facts from misinformation.
Associations between cannabis use, Cannabis Use Disorder, and mood disorders: Longitudinal, genetic, and neurocognitive evidence
Cannabis use is widespread, and rates of use in individuals with depression are increasing faster than in non-depressed individuals. Many report using cannabis to alleviate mood disorder symptoms, but it can also worsen them.
Synaptic changes induced by cannabinoid drugs and Cannabis Use Disorder
Cannabis use is widespread and increasingly popular, despite risks like dependence and withdrawal. While behavioral effects are known, the underlying neurobiological mechanisms are still being explored.
Thalamocortical functional connectivity and cannabis use in men with childhood Attention-Deficit/Hyperactivity Disorder
ADHD symptoms often persist into adulthood, increasing the risk of substance use disorder, including cannabis use. Brain regions like the thalamus may play a role in this increased risk.
Elucidating the Neurobiologic Etiology of Comorbid PTSD and Substance Use Disorders
Early childhood trauma, especially maltreatment, often leads to PTSD in youth. This trauma significantly increases the risk of developing substance use disorders, creating a complex cycle of challenges.
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
This document systematically reviews adverse events reported during or after psychedelic treatments for mental disorders. It identifies challenges in assessing these events due to varied reporting and terminology.
MDMA and memory, addiction, and depression: dose-effect analysis
MDMA shows promise as a psychotherapeutic agent due to its ability to increase empathy and sociality.